139 Global differences in SAB management 6 Table S2. Indications for 18F-FDG PET/CT use in S. aureus bacteremia patients Total N=993 North America N=292 Europe N=398 Asia N=125 Oceania N=124 South America N=50 p Persistent bacteremia 666 (67.1) 203 (69.5) 269 (67.6) 84 (67.2) 78 (62.9) 31 (62.0) 0.66 Signs of metastatic infection 518 (52.2) 115 (39.4) 247 (62.1) 75 (60.0) 41 (33.1) 38 (76.0) <0.01 Persistent fever 48-72h 367 (37.0) 95 (32.5) 169 (42.5) 43 (34.4) 38 (30.6) 22 (44.0) 0.03 Prosthetic joint material 279 (28.1) 60 (20.5) 144 (36.2) 32 (25.6) 25 (20.2) 18 (36.0) <0.01 Suspected endocarditis 311 (31.3) 52 (17.8) 172 (43.2) 34 (27.2) 33 (26.6) 18 (36.0) <0.01 Legend. Values are counts (% of respondents of region who answered the question). N = number of respondents that answered this question. p value refers to difference between continents. Africa was excluded here because 18F-FDG PET/CT was almost never used.
RkJQdWJsaXNoZXIy MTk4NDMw